|
시장보고서
상품코드
2091498
안근마비 시장 규모, 점유율, 성장 분석 : 종류별, 치료법별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Ophthalmoplegia Market Size, Share, and Growth Analysis, By Type (External Ophthalmoplegia, Internuclear Ophthalmoplegia (INO)), By Treatment (Surgery, Drug Treatment), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 안근마비 시장 규모는 2024년에 17억 2,000만 달러로 평가되었으며, 2025년 18억 9,000만 달러에서 2033년까지 39억 9,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 9.8%로 성장할 것으로 전망됩니다.
세계 안근마비 시장은 안구 운동에 영향을 미치는 신경계 및 근계 질환의 발생률 증가에 힘입어 성장하고 있으며, 이는 진단 및 치료 솔루션에 대한 수요를 촉진하고 있습니다. 초기에는 희귀한 선천성 유형에 초점이 맞춰져 있었으나, 당뇨병, 중증근무력증 및 뇌졸중과 관련된 안근마비 사례가 증가함에 따라 시장이 확대되고 있습니다. 최근 역학적 연구 결과에 따르면, 후천성 안근마비 사례가 크게 증가하고 있으며, 이에 따라 각 제약사는 첨단 영상 진단 기술 및 생물학적 제제에 대한 투자를 확대하고 있습니다. 이 분야에서는 침습적인 약물전달 기술이 발전함에 따라, 보툴리눔톡신나 단일클론 항체와 같은 생물학적 제제가 안구 외근을 효과적으로 표적으로 삼을 수 있게 되었습니다. 이러한 높은 정확도는 환자의 예후를 개선하고 입원 기간을 단축할 뿐만 아니라, 치료 순응도 향상으로도 이어지고 있으며, 이에 따라 보험 급여 기관들이 이러한 혁신 기술을 지원하고 치료 파이프라인에 대한 추가 투자를 촉진하고 있습니다.
세계 안근마비 시장의 성장요인
세계 안근마비 시장은 안과 의사 및 신경과 의사들 사이에서 높아지고 있는 임상적 인식에 힘입어 크게 성장하고 있습니다. 이를 통해 이 질환의 조기 발견이 촉진되고, 적시에 치료 방안을 모색할 수 있게 되었습니다. 진단 정확도의 향상은 치료 대상이 되는 환자 수를 늘릴 뿐만 아니라, 전문 의료 서비스로의 의뢰도 촉진하고 있습니다. 그 결과, 혁신적인 의약품 및 의료기기에 대한 수요가 지속되고 있습니다. 이러한 추세는 환자 치료 과정을 개선할 뿐만 아니라 시장 전체의 성장과 확대에도 기여하며, 새로운 치료 옵션의 보급과 치료법의 발전을 촉진하고 있습니다.
세계 안근마비 시장의 제약요인
혁신적인 의약품이나 고도의 외과 수술에 수반되는 고액의 비용은 환자, 의료 서비스 제공자, 보험사에게 큰 경제적 장벽이 되어, 전 세계 안근마비 시장의 광범위한 보급을 저해하고 있습니다. 이러한 고가 구조는, 특히 비용에 민감한 시장에서 보험 급여 승인을 받기 어렵게 만드는 문제가 있으며, 결과적으로 필수적인 치료에 대한 접근을 제한하는 결과로 이어집니다. 그 결과, 가격에 대한 민감도가 판매량 증가를 제한하고, 더 폭넓은 환자층을 대상으로 한 새로운 치료 옵션의 도입을 지연시킬 가능성이 있으며, 궁극적으로는 시장의 전반적인 확대와 잠재력에 영향을 미치게 될 것입니다.
세계 안근마비 시장의 동향
세계 안근마비 시장에서는 분자유전학의 발전을 원동력으로 삼아, 맞춤형 유전자 치료 도입을 향한 뚜렷한 추세가 나타나고 있습니다. 선천성 및 후천성 안근마비 모두에서, 기존의 외과적 치료를 대체할 대안으로 표적 맞춤형 유전자 편집 전략이 등장하고 있습니다. 임상의들은 근본적인 신경 기능 장애를 직접적으로 해결하는 맞춤형 치료 프로토콜을 점점 더 많이 도입하고 있으며, 이를 통해 환자의 예후와 전반적인 삶의 질을 향상시키고 있습니다. 이러한 변화는 생명공학 기업, 학술 기관, 전문 의료 시설 간의 협력을 촉진하고 있으며, 혁신적인 치료제의 탄탄한 파이프라인으로 이어지고 있습니다. 그 결과, 세계 시장의 초기 도입자들은 새로운 수익원과 재정의된 표준 치료 경로의 혜택을 누릴 준비가 되어 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 안근마비 시장 규모 : 유형별
세계의 안근마비 시장 규모 : 치료별
세계의 안근마비 시장 규모 : 최종사용자별
세계의 안근마비 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Ophthalmoplegia Market size was valued at USD 1.72 Billion in 2024 and is poised to grow from USD 1.89 Billion in 2025 to USD 3.99 Billion by 2033, growing at a CAGR of 9.8% during the forecast period (2026-2033).
The global ophthalmoplegia market is driven by an increasing incidence of neurological and muscular disorders affecting eye movement, which boosts the demand for diagnostic and therapeutic solutions. Initially focused on rare congenital types, the market has expanded due to rising cases of diabetes, myasthenia gravis, and stroke-related ocular palsies. Recent epidemiological insights indicate a significant rise in acquired ophthalmoplegia cases, encouraging manufacturers to invest in advanced imaging and biologics. The sector is witnessing advancements in invasive drug delivery technologies, allowing biologic agents like botulinum toxin and monoclonal antibodies to target extraocular muscles effectively. This precision not only improves patient outcomes and reduces hospital recovery times but also enhances compliance, prompting reimbursement agencies to support these innovations and stimulate further investment in the treatment pipeline.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ophthalmoplegia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ophthalmoplegia Market Segments Analysis
Global ophthalmoplegia market is segmented by type, treatment, end user and region. Based on type, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia (INO). Based on treatment, the market is segmented into surgery, drug treatment and rehabilitation (vision therapy). Based on end user, the market is segmented into hospitals & clinics, ambulatory clinics and ophthalmology centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ophthalmoplegia Market
The global ophthalmoplegia market is significantly driven by the growing clinical awareness among ophthalmologists and neurologists, which aids in the prompt recognition of the condition and encourages timely treatment options. This improved diagnostic accuracy not only increases the number of patients who qualify for therapeutic interventions but also promotes referrals to specialized services. As a result, there is a sustained demand for innovative pharmaceuticals and medical devices. This dynamic not only enhances patient care pathways but also contributes to the overall growth and expansion of the market, facilitating the wider adoption of new treatment options and advancements in therapy.
Restraints in the Global Ophthalmoplegia Market
The high costs linked to innovative medications and advanced surgical procedures create significant financial obstacles for patients, healthcare providers, and insurance companies, hindering widespread acceptance in the global ophthalmoplegia market. These elevated pricing structures can lead to challenges in obtaining reimbursement approvals, particularly in markets that are sensitive to costs, which in turn restricts access to essential treatments. As a result, price sensitivity limits the growth of volume sales and may slow the introduction of new therapeutic alternatives to a wider range of patients, ultimately affecting the market's overall expansion and potential.
Market Trends of the Global Ophthalmoplegia Market
The global ophthalmoplegia market is experiencing a significant trend towards the adoption of personalized gene therapy, driven by advances in molecular genetics. Targeted gene-editing strategies are emerging as alternatives to traditional surgical treatments for both congenital and acquired ophthalmoplegia. Clinicians are increasingly adopting personalized therapy protocols that directly address the underlying neural deficits, enhancing patient outcomes and overall quality of life. This shift is fostering collaboration among biotechnology companies, academic institutions, and specialized healthcare facilities, leading to a robust pipeline of innovative therapeutic products. As a result, early adopters in the global market are poised to benefit from new revenue streams and redefined standard care pathways.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Ophthalmoplegia Market Size by Type & CAGR (2026-2033)
- Market Overview
- External Ophthalmoplegia
- Superior Rectus Muscle Palsy
- Inferior Rectus Muscle Palsy
- Medial Rectus Muscle Palsy
- Lateral Rectus Muscle Palsy
- Superior & Inferior Oblique Muscle Palsy
- Internuclear Ophthalmoplegia (INO)
Global Ophthalmoplegia Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Surgery
- Strabismus Surgery
- Other Surgical Procedures
- Drug Treatment
- Corticosteroids
- Botulinum Toxin (Botox) Injection
- Immune Modulators
- Rehabilitation (Vision Therapy)
Global Ophthalmoplegia Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals & Clinics
- Ambulatory Clinics
- Ophthalmology Centers
Global Ophthalmoplegia Market Size & CAGR (2026-2033)
- North America (Type, Treatment, End User)
- US
- Canada
- Europe (Type, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Treatment, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch + Lomb Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Vision Care
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rohto Pharmaceutical Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IPSEN SA (Dysport/Botox)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (Botox)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medytox Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daewoong Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cerephex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oculokinetics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viridian Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Horizon Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
